Skip to content

Psilocybin: all studies

Page 28 of 440: studies 271 to 280 of 4,392, newest first. Back to the psilocybin overview

Research

In-silico toxicity study of tryptamine, psilocin, psilocybin, N,N-dimethyltryptamine, 5'-methoxy-N,N-dimethyltryptamine and O-acetylpsilocin.

Archives of Toxicology March 31, 2026 Kamil Jurowski, Damian Kobylarz, Maciej Noga

Understanding the toxicity of serotonergic tryptamines is becoming increasingly important from both clinical and forensic perspectives, yet experimental data for these compounds remain extremely limited. Despite their growing medical relevance and widespread non-medical use, there is still no systematic evaluation of their toxicological risks. This study presents the first comprehensive in...

DOI: 10.1007/s00204-026-04365-4 (opens in new tab) Full text (opens in new tab) In silico toxicology Computational toxicology Forensic toxicology Tryptamines

Therapist Manual for Psilocybin-Assisted Therapy of Treatment-Resistant Major Depression

Zenodo (CERN European Organization for Nuclear Research) March 30, 2026 preprint

Psilocybin-assisted therapy has emerged as a promising intervention for treatment-resistant depression (TRD), yet standardized and transparent therapeutic frameworks remain limited. This therapist manual was developed for the EPIsoDE trial, a phase IIb randomized clinical study investigating the efficacy and safety of psilocybin with adjunct psychotherapy in patients with TRD (NCT04670081). The...

Psychedelics in NHS services: exploring a model for real-world implementation of psilocybin

The British Journal of Psychiatry March 30, 2026 Katharine A. Smith, Edward Harcourt, Andrea Cipriani 1 citation

Psychedelics are increasingly described as a new therapeutic approach in a variety of mental disorders including depression. Oral psychedelics such as psilocybin have an acute effect evolving over 6-8 h and are generally given in combination with psychological support. There is debate on the exact role of this support and how and by whom it should be delivered. This has significant implications...

Associations Between Psilocybin Use Motives and Cognitive, Affective, and Behavioural Self-Stigma.

Substance Use & Misuse March 28, 2026 Graeme Knibb, Ruby Ward, Paul Christiansen et al.

Background: Self-stigma refers to the internalization of negative societal beliefs and has been associated with reduced self-efficacy, self-esteem and treatment avoidance among substance users. However, little research has explored antecedents of self-stigma such as substance use motives. This may be particularly salient for psilocybin which is used both as a therapeutic agent and a...

Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons.

Elife March 27, 2026 Målin Schmidt, Anne Hoffrichter, Mahnaz Davoudi et al. 3 citations

Psilocybin is studied as innovative medication in anxiety, substance abuse and treatment-resistant depression. Animal studies show that psychedelics promote neuronal plasticity by strengthening synaptic responses and protein synthesis. However, the exact molecular and cellular changes induced by psilocybin in the human brain are not known. Here, we treated human cortical neurons derived from...

Psilocybin Attenuates Cortical Representations of Aversion in the Mouse Auditory Cortex.

bioRxiv : the preprint server for biology March 27, 2026 James D. Johnson, Runyi Tian, Yasaman Etemadi et al. preprint

Psilocybin can produce sustained benefits in affective and trauma-related disorders, yet if and how it reshapes sensory representations of learned valence associations remains largely unclear. To address this, we used longitudinal two-photon calcium imaging in awake C57BL/6 mice to examine how psilocybin modulates layer 2/3 auditory cortex activity at single-cell and population levels. Evoked...

Safety and Efficacy of Psilocybin-Assisted Therapy for Alcohol Use Disorder: Open-Label Extension of a Phase II Randomized Controlled Trial

PsyArXiv March 26, 2026 Broc A. Pagni, Stephen Ross, Sarah E. Mennenga et al. preprint

Background: Psilocybin-assisted therapy (PAT) has shown promise for alcohol use disorder (AUD) in randomized controlled trials (RCTs). However, the effects of open-label administration following blinded treatment are unclear. Here, we present safety and efficacy data from an open-label extension of a Phase II RCT (NCT02061293) examining PAT for AUD. Methods: Adults with AUD (N = 59) received a...

Psilocybin in Neuropsychiatric Disorders: Seeking Valuable Evidence in History, Pure Science, Clinical Trials and Real-World Data (RWD).

Brain Sciences March 26, 2026 Piotr Skalski, Katarzyna Pękacka-falkowska, Agnieszka Pluto-Prądzyńska et al.

Background/Objectives: Psilocybin has re-emerged as a promising intervention for neuropsychiatric disorders including major depressive disorder, treatment-resistant depression, anxiety associated with life-threatening illness, obsessive compulsive disorder, and substance use disorders. However, conventional randomized controlled trials (RCTs)-the current gold standard in evidence-based...

DOI: 10.3390/brainsci16040358 (opens in new tab) Full text (opens in new tab) Evidence Psilocybin-assisted therapy pat Psychopharmacology Real-world data rwd

Psilocybin shapes the slow, global propagation of brain activity over the cortical layout of 5HT2a receptors

Communications Biology March 26, 2026 Veronica Mäki-marttunen 1 citation

Uncovering the neural basis of psychedelics’ potent effects on brain activity and conscious experience has great potential for understanding their therapeutic effects. Numerous studies using functional magnetic resonance imaging (fMRI) uncovered a strong effect of psychedelics on global properties of fMRI signal, but how they map to underlying neural phenomena remains to be further explored. In...

Psilocybin: Chemical Foundations and Emerging Therapeutic Potential.

Mini-Reviews in Medicinal Chemistry March 24, 2026 Shivaputra A Patil, Holly C Hunsberger

Psilocybin, chemically known as (4-phosphoryloxy-N, N-dimethyltryptamine, 4-PODMT), is derived from the psychoactive mushroom genus, Psilocybe. Of the four active metabolites, psilocin readily enters systemic circulation. The psychoactive effects of psilocin are thought to arise through partial agonist effects at the 5-HT2A receptor. Psychedelic drugs, including psilocybin, are having a...